Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Dec 12, 2025

Hims & Hers Expands Weight-Management Program to the United Kingdom

HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.

Zacks Investment Research • Dec 12, 2025

Hims & Hers Expands Its Technology-Driven Personalized Virtual Care

HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.

Zacks Investment Research • Dec 11, 2025

Hims and Hers to offer weight-loss treatments in UK

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United Kingdom which will include drugs like Novo Nordisk's Wegovy, the company said on Wednesday.

Reuters • Dec 10, 2025

Hims & Hers Brings Comprehensive Weight Loss Programme to the UK

LONDON--(BUSINESS WIRE)--Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care. Sixty four percent of UK adults are overweight or living with obesity, yet access to GLP-1 treatment plans remains challenging on the NHS, and via the private sector due to surgin.

Business Wire • Dec 10, 2025

Looking For A Squeeze? Top 10 Most Shorted Stocks Right Now

Traders typically look for heavily shorted stocks for two main reasons: either to bet on a decline in the company's value or to profit from a short squeeze.

Benzinga • Dec 10, 2025

Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?

HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.

Zacks Investment Research • Dec 9, 2025

OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Dec 8, 2025

Hims & Hers: The Market's Panic Is Irrational

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification beyond GLP-1s, reducing regulatory and competitive risks. By assuming very achievable growth rates, the company seems to be undervalued by up to 102%.

Seeking Alpha • Dec 7, 2025

A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity

Hims & Hers Health expands into Canada via Livewell acquisition, targeting a large, underserved weight-loss market. Canadian entry leverages local leadership and expertise, aiming to replicate successful European expansion and accelerate subscriber growth. GLP-1 weight-loss treatments drive revenue potential but introduce margin pressure and cost volatility, creating both opportunity and structural risk.

Seeking Alpha • Dec 5, 2025